Table 1.
Clinical trials on targeting neutrophil relevant strategies in cancers
| Purpose | Targets | Agents | Clinical Trials |
|---|---|---|---|
| Inhibition of recruitment and promotion of apoptosis | CXCR1/ CXCR2 inhibitor | Reparixin | NCT02370238 |
| NCT02001974 | |||
| TRAIL receptor agonists | Tigatuzumab | NCT01307891 | |
| CS-1008 | NCT01220999 | ||
| Mapatumumab | NCT01088347 | ||
| AMG 951 | NCT00508625 | ||
| TRM-1 | NCT00092924 | ||
| Anti- CD40 monoclonal antibody | CP-870, 893 | NCT01103635 | |
| NCT00607048 | |||
| CCR5 antagonists | Maraviroc | NCT03274804 | |
| NCT01736813 | |||
| CD47–SIRPα inhibitors | Hu5F9-G4 | NCT02216409 | |
| IBI188 | NCT03717103 | ||
| CC-90,002 | NCT02367196 | ||
| Inhibition of pro-tumor function | Neutrophil elastase inhibitors | Sivelestat | NCT01170845 |
| PI3K inhibitors | Buparlisib (a PI3Kδγ inhibitor) | NCT02194049 | |
| NCT01629615 | |||
| PDE5 inhibitors | Sildenafil | NCT02544880 | |
| NCT00752115 | |||
| Tadalafil | NCT01697800 | ||
| NSAIDs | Aspirin and ibuprofen (COX1 and COX2 inhibitors) | NCT01786200 | |
| Celecoxib (a COX2 inhibitor) | NCT02429427 | ||
| Enhancing the tumor-promoting function(Switch phenotype) | C/EBPα | MTL-CEBPA small activating RNA | NCT02716012 |
| NCT04105335 | |||
| TGF-β pathway inhibitors | Galunisertib | NCT01582269 | |
| NCT01682187 | |||
| NCT03206177 | |||
| NCT02672475 | |||
| NCT02734160 | |||
| NCT02452008 | |||
| Fresolimumab (an anti- TGFβ monoclonal antibody) | NCT02581787 | ||
| STAT3 inhibitors | Napabucasin (BBI608) | NCT02753127 | |
| NCT02358395 | |||
| β- Glucans | ImuCell WGP | NCT00682032 | |
| Increasing recruitment and longevity | G- CSF mimetics | Pegfilgrastim | NCT00035594 |
| YPEG- rhG-CSF (a long- acting form of pegfilgrastim) | NCT02005458 | ||
| Angiogenesis inhibitors | Plinabulin (an inhibitor of tubulin polymerization, as required for the formation of new blood vessels) | NCT00630110 | |
| NCT02504489 | |||
| NCT03102606 |